Max Lafontan

Expression of Human α2-Adrenergic Receptors in Adipose Tissue of β3-Adrenergic Receptor-deficient Mice Promotes Diet-induced Obesity*

B. Lowell, M. Ito, P. Valet, 2000, The Journal of Biological Chemistry.

Peripheral cardiovascular actions of SR 58611 A, a beta 3‐adrenoceptor agonist, in the dog: lack of central effect

J. Montastruc, M. Pelat, D. Langin, 1999, Fundamental & clinical pharmacology.

Lipolytic effects of conventional β3‐adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative β4‐adrenoceptor

J. Montastruc, D. Langin, M. Berlan, 1997, British journal of pharmacology.

Identification of human platelet a2‐adrenoceptors with a new antagonist [3H]‐RX821002, a 2‐methoxy derivative of idazoxan

J. Montastruc, J. Senard, M. Berlan, 1990, British journal of pharmacology.

Lipomobilizing effects of procaterol and yohimbine in the conscious dog: comparison of endocrinological, metabolic and cardiovascular effects

P. Valet, M. Taouis, M. Berlan, 1989, British journal of pharmacology.

Les cellules endothéliales du tissu adipeux

M. Lafontan, A. Villaret, R. Walther, 2011 .

Evidence for the α2 nature of the α-adrenergic receptor inhibiting lipolysis in human fat cells

M. Berlan, M. Lafontan, Max Lafontan, 1980 .